These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34163906)

  • 21. The binding mechanism of failed, in processing and succeed inhibitors target SARS-CoV-2 main protease.
    Hongyu H; Wu T; He F; Chao M; Huang J; Wang X; Niu Z; Tang B
    J Biomol Struct Dyn; 2023 Sep; ():1-12. PubMed ID: 37735887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease.
    Fadaka AO; Sibuyi NRS; Martin DR; Klein A; Madiehe A; Meyer M
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective covalent targeting of SARS-CoV-2 main protease by enantiopure chlorofluoroacetamide.
    Yamane D; Onitsuka S; Re S; Isogai H; Hamada R; Hiramoto T; Kawanishi E; Mizuguchi K; Shindo N; Ojida A
    Chem Sci; 2022 Mar; 13(10):3027-3034. PubMed ID: 35432850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (M
    Hicks EG; Kandel SE; Lampe JN
    Bioorg Med Chem Lett; 2022 Jun; 66():128732. PubMed ID: 35427739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ebselen derivatives inhibit SARS-CoV-2 replication by inhibition of its essential proteins: PL
    Zmudzinski M; Rut W; Olech K; Granda J; Giurg M; Burda-Grabowska M; Kaleta R; Zgarbova M; Kasprzyk R; Zhang L; Sun X; Lv Z; Nayak D; Kesik-Brodacka M; Olsen SK; Weber J; Hilgenfeld R; Jemielity J; Drag M
    Sci Rep; 2023 Jun; 13(1):9161. PubMed ID: 37280236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of high-affinity inhibitors of SARS-CoV-2 main protease: Towards the development of effective COVID-19 therapy.
    Mohammad T; Shamsi A; Anwar S; Umair M; Hussain A; Rehman MT; AlAjmi MF; Islam A; Hassan MI
    Virus Res; 2020 Oct; 288():198102. PubMed ID: 32717346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. QM/QM studies for Michael reaction in coronavirus main protease (3CL Pro).
    Taranto AG; Carvalho P; Avery MA
    J Mol Graph Model; 2008 Oct; 27(3):275-85. PubMed ID: 18567519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.
    Ancy I; Sivanandam M; Kumaradhas P
    J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Crystal structures of coronaviral main proteases in complex with the non-covalent inhibitor X77.
    Jiang H; Li W; Zhou X; Zhang J; Li J
    Int J Biol Macromol; 2024 Sep; 276(Pt 1):133706. PubMed ID: 38981557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An integrated metabolomic and proteomic approach for the identification of covalent inhibitors of the main protease (M
    Baron G; Borella S; Della Vedova L; Vittorio S; Vistoli G; Carini M; Aldini G; Altomare A
    Talanta; 2023 Jan; 252():123824. PubMed ID: 36027618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of C-12 dithiocarbamate andrographolide analogues as inhibitors of SARS-CoV-2 main protease:
    Nutho B; Wilasluck P; Deetanya P; Wangkanont K; Arsakhant P; Saeeng R; Rungrotmongkol T
    Comput Struct Biotechnol J; 2022; 20():2784-2797. PubMed ID: 35677603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure of M
    Jin Z; Du X; Xu Y; Deng Y; Liu M; Zhao Y; Zhang B; Li X; Zhang L; Peng C; Duan Y; Yu J; Wang L; Yang K; Liu F; Jiang R; Yang X; You T; Liu X; Yang X; Bai F; Liu H; Liu X; Guddat LW; Xu W; Xiao G; Qin C; Shi Z; Jiang H; Rao Z; Yang H
    Nature; 2020 Jun; 582(7811):289-293. PubMed ID: 32272481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors.
    Tan B; Sacco M; Tan H; Li K; Joyce R; Zhang X; Chen Y; Wang J
    Eur J Med Chem; 2023 Nov; 259():115667. PubMed ID: 37482021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interaction of panduratin A and derivatives with the SARS-CoV-2 main protease (m
    Vergoten G; Bailly C
    J Biomol Struct Dyn; 2023; 41(14):6834-6844. PubMed ID: 35975613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening of plant-based natural compounds as a potential COVID-19 main protease inhibitor: an
    Majumder R; Mandal M
    J Biomol Struct Dyn; 2022 Feb; 40(2):696-711. PubMed ID: 32897138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals.
    Ma Y; Yang KS; Geng ZZ; Alugubelli YR; Shaabani N; Vatansever EC; Ma XR; Cho CC; Khatua K; Xiao J; Blankenship LR; Yu G; Sankaran B; Li P; Allen R; Ji H; Xu S; Liu WR
    Eur J Med Chem; 2022 Oct; 240():114570. PubMed ID: 35779291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Drug Repurposing Approach to Identify Therapeutics by Screening Pathogen Box Exploiting SARS-CoV-2 Main Protease.
    Tyagi R; Paul A; Raj VS; Ojha KK; Kumar S; Panda AK; Chaurasia A; Yadav MK
    Chem Biodivers; 2023 Feb; 20(2):e202200600. PubMed ID: 36597267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals.
    Alugubelli YR; Geng ZZ; Yang KS; Shaabani N; Khatua K; Ma XR; Vatansever EC; Cho CC; Ma Y; Xiao J; Blankenship LR; Yu G; Sankaran B; Li P; Allen R; Ji H; Xu S; Liu WR
    Eur J Med Chem; 2022 Oct; 240():114596. PubMed ID: 35839690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determination of potential inhibitors based on isatin derivatives against SARS-CoV-2 main protease (m
    Badavath VN; Kumar A; Samanta PK; Maji S; Das A; Blum G; Jha A; Sen A
    J Biomol Struct Dyn; 2022 Apr; 40(7):3110-3128. PubMed ID: 33200681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pre-Steady-State Kinetics of the SARS-CoV-2 Main Protease as a Powerful Tool for Antiviral Drug Discovery.
    Zakharova MY; Kuznetsova AA; Uvarova VI; Fomina AD; Kozlovskaya LI; Kaliberda EN; Kurbatskaia IN; Smirnov IV; Bulygin AA; Knorre VD; Fedorova OS; Varnek A; Osolodkin DI; Ishmukhametov AA; Egorov AM; Gabibov AG; Kuznetsov NA
    Front Pharmacol; 2021; 12():773198. PubMed ID: 34938188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.